Theratechnologies Announces Completion of Acquisition by Future Pak
1. THTX was acquired by CB Biotechnology at US$3.01 per share. 2. Each former THTX shareholder receives cash plus a contingent value right. 3. Shares will be delisted from TSX and NASDAQ on September 26 and 25, 2025. 4. Contingent value rights offer potential additional payments based on company milestones. 5. Company will cease to be a reporting issuer under Canadian laws.